Subscribe To
Eur/gbp weekly outlook
EUR/GBP reversed after edging higher to 0.8752 last week. Current development suggests that price actions from 0.8752 are correcting whole rally from ...
November 4, 2023, 1:12 pm
Avanos medical inc. (avns) q3 2023 earnings call transcript
Avanos Medical Inc. (NYSE:AVNS ) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Scott Galovan - SVP, Strategy and C...
November 4, 2023, 12:02 pm
The often overlooked and misunderstood bond buy
By Eric Fine, Portfolio Manager, Emerging Markets Fixed Income Rising rates and emerging risks in developed markets could spell trouble for bond portf...
November 4, 2023, 11:29 am
Lisata therapeutics, inc. (lsta) q3 2023 earnings call transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants John Menditto - VP, IR and C...
November 4, 2023, 10:27 am
Oil prices forecast: wti & brent traders weigh economic headwinds
OPEC+ decisions and EIA inventory reports to drive oil market sentiment in the face of global economic and policy developments....
November 4, 2023, 7:50 am
Boeing stock: buy, sell, or hold?
Boeing is struggling to meet its near-term aims on airplane production ramps and fixed-price development contracts. The stock continues to look a good...
November 4, 2023, 7:47 am
Kefi gold and copper: a comprehensive update on operational progress and market dynamics - icymi
In this interview, Thomas Warner from Proactive chats with Harry Anagnostaras-Adams, the executive chairman of KEFI Gold and Copper PLC (AIM:KEFI, OT...
November 4, 2023, 5:29 am
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Oncolytics biotech inc. (oncy) q3 2023 earnings call transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, IR Mat...
November 3, 2023, 9:05 pm
Aligos therapeutics to host kol event to discuss alg-000184 phase 1, aasld late breaker data
November 16 Event to feature KOL perspective on Emerging HBV Therapies SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — Aligos Therapeu...
November 3, 2023, 8:30 pm
Bdc weekly review: are bond swappers insulated from interest rate rises?
We take a look at the action in business development companies through the fourth week of October and highlight some of the key themes we are watching...
November 3, 2023, 8:19 pm
November 2023 letter to shareholders
VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) — Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Compan...
November 3, 2023, 8:02 pm
New preliminary clinical data on potential of opus aav-based gene therapy for rare inherited retinal disease to be presented at the american academy of ophthalmology annual conference 2023
Data to be presented as part of gene augmentation therapy presentation RALEIGH, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focu...
November 3, 2023, 7:43 pm
Taysha gene therapies: tsha-102's potential is a 'buy'
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting R...
November 3, 2023, 7:41 pm
Ero copper corp. (ero) q3 2023 earnings call transcript
Ero Copper Corp. (NYSE:ERO ) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Courtney Lynn - Senior Vice President, ...
November 3, 2023, 6:58 pm
Cellectis: end of 2023 data readouts to boost car-t prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin...
November 3, 2023, 6:57 pm
Pec gears up for nasdaq listing with $1 billion brand partner subsidy
Pine Bluff, AR, Nov. 03, 2023 (GLOBE NEWSWIRE) — In a landmark development that’s set to redefine brand distribution, Partner E-Commerce (PEC) is ...
November 3, 2023, 5:00 pm